The excitement around private equity dealmaking is expected to continue at a rapid pace through 2022, even as private equity funds across the globe are keeping an eye on high valuations and challenging macroeconomic pressures. While managers remain bullish on the outlook, they are also aware that the current market is not free from risk and this only demonstrates the need for strong value creation plans, sector expertise and the ability to source deals.
Wage inflation, supply chain issues, competition for talent, geo-political risk and stiff competition from strategic buyers are all impacting the way middle market private equity firms are approaching their dealmaking.
How are private equity investors distinguishing themselves in a competitive deal market? What should a company or founder expect if it takes private equity investment? How are private equity investors changing their investment criteria in a shifting macroeconomic landscape? What is unique about middle market private equity M&A in today’s market? What are the updates in fundraising and limited partner dynamics?
Join us on June 8th at 1:00pm Eastern as The Deal along with global law firm Pillsbury Winthrop Shaw Pittman LLP hosts a roundtable of leading private equity investors on key, developing topics in private equity, M&A and investments.
Brian McKenna has a broad transactional practice that covers mergers and acquisitions as well as strategic and investment transactions on a global basis.
Please fill out the form to watch the video replay of the webcast on demand.
In September 2022, the deals and dealmakers shaping the Deal Economy will be celebrated in the latest installment of The Deal Awards. In line with its mission of providing forward-looking intelligence across mergers and acquisitions, private equity, activism and restructuring, the Awards seek to recognize and celebrate the advisers, firms and banks driving the market forward.
The year’s biggest healthcare deals have focused on acquiring digital capabilities, such as digital care and cloud-based platforms, and Digital Health deal makers are likely to continue to focus on revenue and operational synergies.